Clinical Journal of the American Society of Nephrology

Journal

Publication Venue For

  • PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT..  13:1816-1824. 2018
  • Association of Preexisting Arterial Intimal Hyperplasia with Arteriovenous Fistula Outcomes..  13:1358-1363. 2018
  • Postoperative Ultrasound, Unassisted Maturation, and Subsequent Primary Patency of Arteriovenous Fistulas..  13:1364-1372. 2018
  • Expand the Pool of Living Donors for Kidney Transplantation..  13:1142-1143. 2018
  • Thrombotic Microangiopathy in a Transplant Recipient..  13:1251-1253. 2018
  • Overcoming Translational Barriers in Acute Kidney Injury: A Report from an NIDDK Workshop..  13:1113-1123. 2018
  • Clinical trial end points for hemodialysis vascular access: Background, rationale, and definitions.  13:490-494. 2018
  • Definitions and end points for interventional studies for arteriovenous dialysis access.  13:501-512. 2018
  • Recommended clinical trial end points for dialysis catheters.  13:495-500. 2018
  • Perspectives from the Kidney Health Initiative on Advancing Technologies to Facilitate Remote Monitoring of Patient Self-Care in RRT..  12:1900-1909. 2017
  • Vascular Access Type and Clinical Outcomes among Elderly Patients on Hemodialysis..  12:1823-1830. 2017
  • Challenges in Developing New Therapies for Vascular Access Dysfunction..  12:2053-2055. 2017
  • Managing Issues in Dialysis for the Patient with AKI..  12:1538-1542. 2017
  • Survival Benefit of Transplantation with a Deceased Diabetic Donor Kidney Compared with Remaining on the Waitlist..  12:974-982. 2017
  • Reassessing Recommendations for Choice of Vascular Access..  12:865-867. 2017
  • The Use of a Multidimensional Measure of Dialysis Adequacy-Moving beyond Small Solute Kinetics..  12:839-847. 2017
  • Access to Kidney Transplantation among HIV-Infected Waitlist Candidates..  12:467-475. 2017
  • Diagnosis, Treatment, and Prevention of Hemodialysis Emergencies..  12:357-369. 2016
  • Predictors of Initiation for Predialysis Arteriovenous Fistula..  11:1802-1808. 2016
  • Association of Peritonitis with Hemodialysis Catheter Dependence after Modality Switch..  11:1999-2004. 2016
  • Preoperative Vascular Medial Fibrosis and Arteriovenous Fistula Development..  11:1615-1623. 2016
  • Paraprotein-Related Kidney Disease: Kidney Injury from Paraproteins-What Determines the Site of Injury?.  11:2288-2294. 2016
  • New Insights into Dialysis Vascular Access: Impact of Preexisting Arterial and Venous Pathology on AVF and AVG Outcomes..  11:1495-1503. 2016
  • New Insights into Dialysis Vascular Access: Introduction..  11:1484-1486. 2016
  • New Insights into Dialysis Vascular Access: Molecular Targets in Arteriovenous Fistula and Arteriovenous Graft Failure and Their Potential to Improve Vascular Access Outcomes..  11:1504-1512. 2016
  • Acute Kidney Injury Urine Biomarkers in Very Low-Birth-Weight Infants..  11:1527-1535. 2016
  • Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT..  11:1377-1383. 2016
  • Association of Reduced eGFR and Albuminuria with Serious Fall Injuries among Older Adults..  11:1236-1243. 2016
  • Automated Segmentation of Kidneys from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease..  11:576-584. 2016
  • Genetic African Ancestry and Markers of Mineral Metabolism in CKD..  11:653-662. 2016
  • Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT..  11:471-480. 2016
  • A Patient with Recurrent Arteriovenous Graft Thrombosis..  10:2255-2262. 2015
  • Serum Uric Acid and Risk of CKD in Type 2 Diabetes..  10:1921-1929. 2015
  • The Ethics of Chronic Dialysis for the Older Patient: Time to Reevaluate the Norms..  10:2094-2099. 2015
  • A Prospective International Multicenter Study of AKI in the Intensive Care Unit..  10:1324-1331. 2015
  • The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial..  10:791-799. 2015
  • Progression of pediatric CKD of nonglomerular origin in the CKiD cohort..  10:571-577. 2015
  • Identification of strategies to facilitate organ donation among African Americans using the nominal group technique..  10:286-293. 2015
  • Nephrotoxic effects of common and emerging drugs of abuse..  9:1996-2005. 2014
  • Nondisease-specific problems and all-cause mortality among older adults with CKD: the REGARDS Study..  9:1737-1745. 2014
  • A patient with AKI after cardiac surgery..  9:1470-1478. 2014
  • The demented patient who declines to be dialyzed and the unhappy armed police officer son: what should be done?.  9:804-808. 2014
  • Renal relevant radiology: use of ultrasonography in patients with AKI..  9:382-394. 2014
  • Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study..  9:64-71. 2014
  • Metabolic subtypes and risk of mortality in normal weight, overweight, and obese individuals with CKD..  8:2064-2071. 2013
  • Novel paradigms for dialysis vascular access: Introduction..  8:2183-2185. 2013
  • Novel paradigms for dialysis vascular access: downstream vascular biology--is there a final common pathway?.  8:2194-2201. 2013
  • Preoperative venous intimal hyperplasia, postoperative arteriovenous fistula stenosis, and clinical fistula outcomes..  8:1750-1755. 2013
  • Prevalence of apparent treatment-resistant hypertension among individuals with CKD..  8:1583-1590. 2013
  • Future of Medicare immunosuppressive drug coverage for kidney transplant recipients in the United States..  8:1258-1266. 2013
  • Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease..  8:1089-1097. 2013
  • Age at graft loss after pediatric kidney transplantation: exploring the high-risk age window..  8:1019-1026. 2013
  • Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD..  8:1009-1018. 2013
  • Long-term outcomes of arteriovenous thigh grafts in hemodialysis patients: a comparison with tunneled dialysis catheters..  8:804-809. 2013
  • AKI associated with synthetic cannabinoids: a case series..  8:523-526. 2013
  • A case of late kidney allograft failure: a clinical pathological conference from American Society of Nephrology Kidney Week 2011..  7:1884-1889. 2012
  • Comparative effects of low-carbohydrate high-protein versus low-fat diets on the kidney..  7:1103-1111. 2012
  • Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR..  7:989-1002. 2012
  • Design of clinical trials in AKI: a report from an NIDDK workshop. Trials of patients with sepsis and in selected hospital settings..  7:856-860. 2012
  • Design of clinical trials in acute kidney injury: a report from an NIDDK workshop--prevention trials..  7:851-855. 2012
  • Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology..  7:844-850. 2012
  • Use of secondary prevention medications among adults with reduced kidney function..  7:604-611. 2012
  • Academic interventional nephrology: a model for training, research, and patient care..  7:521-524. 2012
  • Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease..  7:479-486. 2012
  • Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT..  7:452-457. 2012
  • (1-34) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers..  7:139-145. 2012
  • Racial differences in the incidence of chronic kidney disease..  7:101-107. 2012
  • Age-specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complications..  6:2822-2828. 2011
  • Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study..  6:2871-2878. 2011
  • Late graft loss among pediatric recipients of DCD kidneys..  6:2705-2711. 2011
  • Age-specific association of reduced estimated glomerular filtration rate and albuminuria with all-cause mortality..  6:2200-2207. 2011
  • The spectrum of infections in catheter-dependent hemodialysis patients..  6:2247-2252. 2011
  • Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy..  6:1903-1911. 2011
  • Arteriovenous graft infection: a comparison of thigh and upper extremity grafts..  6:1739-1743. 2011
  • Barriers to evaluation and wait listing for kidney transplantation..  6:1760-1767. 2011
  • Introduction to the well-transplant visit--more than vital signs and a creatinine check..  6:1773. 2011
  • Decreased cumulative access survival in arteriovenous fistulas requiring interventions to promote maturation..  6:575-581. 2011
  • Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease..  6:640-647. 2011
  • Dialysis fistula or graft: the role for randomized clinical trials..  5:2348-2354. 2010
  • Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry..  5:2220-2228. 2010
  • Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability..  5:2069-2074. 2010
  • Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis..  5:1710-1716. 2010
  • Introduction to the third annual rostand vitamin D symposium..  5:1696. 2010
  • Vitamin D, blood pressure, and African Americans: toward a unifying hypothesis..  5:1697-1703. 2010
  • Does the heparin lock concentration affect hemodialysis catheter patency?.  5:1458-1462. 2010
  • Statin therapy is not associated with improved vascular access outcomes..  5:1447-1450. 2010
  • Optimizing medication adherence: an ongoing opportunity to improve outcomes after kidney transplantation..  5:1305-1311. 2010
  • Development, implementation, and results of the ASN in-training examination for fellows..  5:328-334. 2010
  • Enzyme replacement therapy and Fabry nephropathy..  5:371-378. 2010
  • Introduction to Focus on Fabry nephropathy: biomarkers, progression, and disease severity..  5:359. 2010
  • A Festschrift honoring Dr. John J. Curtis..  4:2027-2028. 2009
  • Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm..  4:2029-2034. 2009
  • Does heparin coating improve patency or reduce infection of tunneled dialysis catheters?.  4:1787-1790. 2009
  • Mineralocorticoid receptor blockers and chronic kidney disease..  4:1685-1691. 2009
  • Clinical outcomes of dialysis catheter-related candidemia in hemodialysis patients..  4:1102-1105. 2009
  • Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis..  4:560-566. 2009
  • Must health literacy be a prerequisite for kidney transplantation?.  4:16-17. 2009
  • Outcomes of brachiocephalic fistulas, transposed brachiobasilic fistulas, and upper arm grafts..  4:86-92. 2009
  • Introduction to Vitamin D Symposium, March 14, 2008..  3:1534. 2008
  • Evaluation and initial management of acute kidney injury..  3:962-967. 2008
  • Delivery of renal replacement therapy in acute kidney injury: what are the key issues?.  3:869-875. 2008
  • Development of a clinical research agenda for acute kidney injury using an international, interdisciplinary, three-step modified Delphi process..  3:887-894. 2008
  • Leflunomide therapy in kidney transplantation: ready for prime time?.  3:652-653. 2008
  • Care of the kidney transplant recipient..  3 Suppl 2:S27-S28. 2008
  • Disparities in fistula maturation persist despite preoperative vascular mapping..  3:437-441. 2008
  • Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference..  3:471-480. 2008
  • Late kidney allograft loss: what we know about it, and what we can do about it..  3 Suppl 2:S56-S67. 2008
  • Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients..  3:69-77. 2008
  • Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study..  2:1131-1139. 2007
  • Reliability of urinary albumin, total protein, and creatinine assays after prolonged storage: the Family Investigation of Nephropathy and Diabetes..  2:1156-1162. 2007
  • Role of beta3 integrin in acute renal allograft rejection in humans..  2:1268-1273. 2007
  • Current management of vascular access..  2:786-800. 2007
  • Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes..  2:431-439. 2007
  • Aldosteronism and hypertension..  1:1039-1045. 2006
  • Survival advantage of black patients with kidney disease after acute myocardial infarction..  1:993-999. 2006
  • Beyond histology: novel tools to diagnose allograft dysfunction..  1:358-366. 2006
  • Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group..  1:467-474. 2006
  • A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance..  1:79-87. 2006
  • International Standard Serial Number (issn)

  • 1555-9041
  • Electronic International Standard Serial Number (eissn)

  • 1555-905X